# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Charles Darwin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI003-SYN-TD
- Date: 1849-06-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Bernard Ashworth, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month review of cyclic vomiting syndrome on amitriptyline. **S**

## History of present illness

Mr. Darwin returns eight weeks after starting amitriptyline. The dose was raised to 50 mg after two weeks and to 75 mg four weeks ago, by portal message. He had one episode two weeks into treatment; he took the sumatriptan spray and an ondansetron tablet within half an hour of the prodrome, and it settled in about ten hours without emergency care. He has had no episode in the four weeks since reaching 75 mg, and his cold three weeks ago passed without one. He has a dry mouth, mild constipation, and some grogginess in the first hour of the morning, and has gained 1 kg. He has no dizziness on standing, palpitations outside the prodrome, or urinary hesitancy. He practices the relaxation breathing most evenings and has not yet started cognitive behavioral therapy. No ECG was done at the 50 mg step, because the increase was made by portal message. **S**

| Element | Detail |
|---|---|
| Medicine | Amitriptyline 75 mg at bedtime for four weeks |
| Episodes | One in eight weeks, aborted at the prodrome; none at 75 mg |
| Side effects | Dry mouth, mild constipation, morning grogginess; weight up 1 kg |
| Self-management | Relaxation breathing most evenings; trigger plan followed |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Positive | Mild constipation; no vomiting in four weeks |
| Ears, nose, mouth, and throat | Positive | Dry mouth |
| Cardiovascular | Negative | No palpitations, chest pain, or fainting |
| Neurological | Positive | Grogginess in the first hour of the morning; no dizziness on standing |
| Psychiatric | Negative | Mood steady; less worried about going out; no thoughts of self-harm |

5 systems reviewed. **S**

## Current medications

- Amitriptyline 75 mg oral tablet, one tablet at bedtime **S**
- Sumatriptan 20 mg nasal spray, one spray at the first sign of an episode **S**
- Ondansetron 8 mg orally disintegrating tablet at the first sign of an episode **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/74 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 72.4 kg; BMI 21.6 kg/m². All vital signs are synthetic.

QTc (ECG): 436 ms; GAD-7: 6; PHQ-9: 4. All results are synthetic.

## Change since baseline

- QTc (ECG): 412 ms at baseline, 436 ms at this visit **S**
- GAD-7: 8 at baseline, 6 at this visit **S**
- PHQ-9: 6 at baseline, 4 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 72.4 kg |
| Cardiovascular | Regular rhythm at 72 per minute; blood pressure 118/74 mmHg, with no drop on standing |
| Abdomen | Soft and non-tender |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Cyclic vomiting syndrome, provisional** (R11.15). Early response to amitriptyline: one aborted episode in eight weeks against about two a month before treatment, and none at the target dose. QTc 436 ms at 75 mg, below 450. Anticholinergic side effects are mild. The ECG at the 50 mg step was missed; today's normal tracing at the higher dose shows no harm resulted. **S**
   - Continue amitriptyline 75 mg at bedtime; judge the response after three months at this dose.
   - More fluid and fiber for the constipation; sugar-free lozenges for the dry mouth.
   - Any future dose change to be made at a visit or with an ECG ordered at the same time.
   - Continue the abortive plan, trigger plan, and relaxation breathing.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Episode diary: number, length, and severity of episodes, prodrome, emergency visits, and missed work | Every visit | Completed today | One episode in eight weeks, about ten hours, aborted at the prodrome; none in four weeks at 75 mg |
| Examination | Rome IV criteria and red flags (vomiting between episodes, weight loss, nocturnal pain, neurological signs, onset after 50) | At diagnosis and with any change in pattern | Completed today | Pattern unchanged; no red flags |
| Laboratory | Blood count, electrolytes and glucose, liver panel, lipase, urinalysis, TSH, cortisol, celiac serology | At diagnosis between episodes; repeat only for an atypical episode | Up to date | Normal at diagnosis; no atypical episode to prompt a repeat |
| Imaging | Upper endoscopy and small-bowel imaging (CT enterography) | Once at diagnosis | Up to date | Normal at diagnosis; no repeat needed |
| Imaging | Gastric emptying study | Not routine; only between episodes when gastroparesis is suspected | Not indicated | No symptoms of gastroparesis |
| Medication safety | ECG with QTc on amitriptyline and ondansetron (below 450 ms in men) | Baseline, at about 50 mg during titration, and at the target dose | Deferred | The ECG due at about 50 mg was not done, a deviation from the guideline: the dose was raised by portal message without an ECG order. Judging by today's tracing at 75 mg (QTc 436 ms, sinus rhythm), no harm resulted. Corrective action: dose changes are now made at a visit or with an ECG ordered at the same time |
| Medication safety | ECG with QTc on amitriptyline and ondansetron (below 450 ms in men) | Baseline, at about 50 mg during titration, and at the target dose | Completed today | QTc 436 ms at the target dose of 75 mg, up from 412 ms at baseline and below 450 ms; sinus rhythm at 72 |
| Medication safety | Amitriptyline tolerability: drowsiness, dry mouth, constipation, dizziness on standing, weight | Each visit on treatment | Completed today | Dry mouth, mild constipation, morning grogginess; weight 72.4 kg (up 1.0 kg); no dizziness on standing |
| Survey | Mood and thoughts of self-harm on a tricyclic (PHQ-9) | Each visit on treatment | Completed today | PHQ-9 4, with item 9 scored 0 |
| Survey | Anxiety screen (GAD-7) | At diagnosis, then every three months | Completed today | GAD-7 6, down from 8 |
| Medication safety | Abortive plan: timing and response to sumatriptan nasal spray and ondansetron, and dose limits | Every visit | Completed today | Used once, within half an hour of the prodrome, with the episode settling in about ten hours; within dose limits |
| Self-management | Individualized emergency department protocol letter | At diagnosis; update with any change in treatment | Up to date | Letter carried; not needed |
| Self-management | Triggers: sleep, meals, travel, social stress, infections | Every visit | Completed today | Regular meals and sleep kept; a cold three weeks ago passed without an episode |
| Self-management | Cannabis and other substance use, and hot-bathing behavior (cannabinoid hyperemesis syndrome) | At diagnosis and yearly | Up to date | No cannabis use |
| Examination | Comorbidities: migraine, orthostatic and autonomic symptoms, sleep disorders | At diagnosis and yearly | Up to date | No migraine or orthostatic symptoms; sleep regular |
| Medication safety | Mitochondrial supplements (coenzyme Q10, riboflavin) | Conditional; consider with a partial response | Not indicated | Early response to amitriptyline; reconsider only if the response becomes partial |
| Medication safety | Alternative prophylaxis (topiramate or aprepitant) | Only if amitriptyline fails or is not tolerated | Not indicated | Amitriptyline effective and tolerated |
| Self-management | Relaxation training, meditation, or biofeedback; cognitive behavioral therapy offered | Ongoing | Completed today | Breathing practice most evenings; cognitive behavioral therapy still offered |
| Examination | Weight and hydration | Every visit | Completed today | 72.4 kg; well hydrated |

## Goal progress

- Complete the work-up between episodes (blood and urine tests, ECG, CT enterography, and upper endoscopy) before the six-week visit. Outcome by 1849-04-14: All tests normal; Rome IV criteria met; provisional diagnosis of cyclic vomiting syndrome at the consultation. **S**
- At least half as many episodes after three months at the target dose of prophylaxis. In progress; target 1849-09-08. **S**
- Carry the abortive medicines and the emergency department letter, and use them at the prodrome. Outcome by 1849-06-09: The one episode since starting treatment was treated at the prodrome and settled in about ten hours without an emergency visit; letter carried. **S**
- QTc below 450 ms at the target amitriptyline dose. Outcome by 1849-06-09: QTc 436 ms on 75 mg. **S**
- Practice relaxation breathing most days and lower the GAD-7 score by the six-month review. In progress; target 1849-09-08. **S**

## Guideline basis

- Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association (2019), American Neurogastroenterology and Motility Society and Cyclic Vomiting Syndrome Association (Neurogastroenterology & Motility)
- Anxiety Disorders in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Preventive health visit in about six weeks. Six-month review in three months, after three months at the target dose. **S**
- Next scheduled visit 1849-07-21: preventive health visit. **S**
